Leerink Partnrs Has Pessimistic Outlook of TMO Q4 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Research analysts at Leerink Partnrs cut their Q4 2024 earnings estimates for shares of Thermo Fisher Scientific in a note issued to investors on Wednesday, October 23rd. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $5.97 per share for the quarter, down from their prior estimate of $6.04. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $21.72 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific’s Q1 2025 earnings at $5.59 EPS, Q2 2025 earnings at $5.77 EPS, Q3 2025 earnings at $5.79 EPS, Q4 2025 earnings at $6.67 EPS, FY2025 earnings at $23.81 EPS and FY2026 earnings at $26.49 EPS.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. Thermo Fisher Scientific’s revenue was up .2% on a year-over-year basis. During the same period last year, the business posted $5.69 earnings per share.

A number of other research analysts have also recently weighed in on the stock. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Monday, September 16th. Evercore ISI decreased their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday. Royal Bank of Canada decreased their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $554.38 on Friday. Thermo Fisher Scientific has a fifty-two week low of $420.21 and a fifty-two week high of $627.88. The company’s 50-day moving average is $605.12 and its 200 day moving average is $584.00. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. The company has a market capitalization of $211.77 billion, a P/E ratio of 34.39, a price-to-earnings-growth ratio of 3.75 and a beta of 0.77.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of large investors have recently bought and sold shares of the stock. Brookstone Capital Management increased its stake in shares of Thermo Fisher Scientific by 252.4% in the first quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock worth $2,550,000 after buying an additional 3,142 shares during the period. New England Research & Management Inc. purchased a new position in shares of Thermo Fisher Scientific in the first quarter valued at about $349,000. KRS Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 6.2% during the first quarter. KRS Capital Management LLC now owns 1,430 shares of the medical research company’s stock worth $831,000 after purchasing an additional 83 shares during the period. S.E.E.D. Planning Group LLC increased its holdings in Thermo Fisher Scientific by 3.8% during the 1st quarter. S.E.E.D. Planning Group LLC now owns 10,178 shares of the medical research company’s stock valued at $5,916,000 after purchasing an additional 371 shares during the period. Finally, Independence Bank of Kentucky raised its position in Thermo Fisher Scientific by 4.3% during the 1st quarter. Independence Bank of Kentucky now owns 2,715 shares of the medical research company’s stock valued at $1,578,000 after purchasing an additional 112 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 6,300 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,548,375.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.